HU-210: Difference between revisions
m (Protected "HU-210": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
| Line 20: | Line 20: | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
'''HU-210''' is a [[Chemical synthesis|synthetic]] [[cannabinoid]] that was discovered around 1988 in the group of Dr Raphael Mechoulam at the Hebrew University. HU-210 is 100 to 800 times more potent than natural [[Tetrahydrocannabinol|THC]] from cannabis and has an extended duration of action.[http://books.nap.edu/html/marimed/ch2_t2.html] HU-210 is the ''(+)''-1,1-dimethylheptyl analog of 7-hydroxy-''delta''-6-tetrahydrocannabinol. The abbreviation ''HU'' stands for ''Hebrew University''. | '''HU-210''' is a [[Chemical synthesis|synthetic]] [[cannabinoid]] that was discovered around 1988 in the group of Dr Raphael Mechoulam at the Hebrew University. HU-210 is 100 to 800 times more potent than natural [[Tetrahydrocannabinol|THC]] from cannabis and has an extended duration of action.[http://books.nap.edu/html/marimed/ch2_t2.html] HU-210 is the ''(+)''-1,1-dimethylheptyl analog of 7-hydroxy-''delta''-6-tetrahydrocannabinol. The abbreviation ''HU'' stands for ''Hebrew University''. | ||
| Line 58: | Line 58: | ||
{{Cannabinoids}} | {{Cannabinoids}} | ||
[[Category:Cannabinoids]] | [[Category:Cannabinoids]] | ||
[[de:Dexanabinol]] | [[de:Dexanabinol]] | ||
[[it:HU-210]] | [[it:HU-210]] | ||
Latest revision as of 15:46, 9 August 2012
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C25H38O3 |
| Molar mass | 386.567 g/mol |
|
WikiDoc Resources for HU-210 |
|
Articles |
|---|
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on HU-210 at Clinical Trials.gov Clinical Trials on HU-210 at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on HU-210
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Directions to Hospitals Treating HU-210 Risk calculators and risk factors for HU-210
|
|
Healthcare Provider Resources |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
HU-210 is a synthetic cannabinoid that was discovered around 1988 in the group of Dr Raphael Mechoulam at the Hebrew University. HU-210 is 100 to 800 times more potent than natural THC from cannabis and has an extended duration of action.[1] HU-210 is the (+)-1,1-dimethylheptyl analog of 7-hydroxy-delta-6-tetrahydrocannabinol. The abbreviation HU stands for Hebrew University.
Per a 2005 article in the Journal Of Clinical Investigation, HU-210 with daily high doses over a few weeks stimulates neural growth in rats' hippocampus region, the opposite effect of drugs like alcohol, nicotine, heroin, and cocaine. It was also indicated by this increased neural growth to entail antianxiety and antidepressant effects.
HU-210, along side WIN 55,212-2 and JWH-133, is implicated in preventing the inflammation caused by Amyloid beta proteins involved in Alzheimer's Disease, in addition to preventing cognitive impairment and loss of neuronal markers. This anti-inflammatory action is induced through the agonization of cannabinoid receptors which prevents microglial activation that elicits the inflammation. Additionally, cannabinoids completely abolish neurotoxicity related to microglia activation in rat models.
HU-210 is a potent analgesic with many of the same effects as natural THC. This means that HU-210 could potentially be used in medicine as an alternative to medical marijuana, however its much stronger and longer lasting effects compared to those of THC could make appropriate titration of dosage difficult. Also because HU-210 is a CB1 full agonist as opposed to THC which is a partial agonist, the sedative effects of HU-210 are much more prominent, meaning that while fatal overdoses of THC itself are virtually impossible[2], they would be possible with HU-210.
External links
- Wen Jiang; et al. (2005). "Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic and antidepressant-like effects". The Journal of Clinical Investigation. Scientific article about nerve cell growth.
- Geoff Brumfiel (2005). "Marijuana may make your brain grow. Cannabinoid injections sprout new neurons in mice". Nature. Unknown parameter
|month=ignored (help); Text " url ? http://www.nature.com/news/2005/051010/full/051010-12.html
- Geoff Brumfiel (2005). "Marijuana may make your brain grow. Cannabinoid injections sprout new neurons in mice". Nature. Unknown parameter
" ignored (help) Comment in Nature on the article.
- Belén G. Ramírez, Cristina Blázquez, Teresa Gómez del Pulgar, Manuel Guzmán, and María L. de Ceballos (2005). "Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation". The Journal of Neuroscience.
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- CS1 maint: Explicit use of et al.
- Pages with citations using unsupported parameters
- Pages with citations using unnamed parameters
- CS1 maint: Multiple names: authors list
- Cannabinoids